Close Menu

OpGen

The test is based on a biomarker signature that consists of a core set of 31 genes associated with endotoxin tolerance in sepsis patients.

The company said it will use the proceeds for research, development, product manufacturing, and other general corporate purposes.

As LDT developers await an FDA decision on potential new regulations and grapple with reimbursement issues, investors may be unwilling to deal with the uncertainty.   

The company attributed the increase in revenue to a $700,000 increase in product sales, particularly its rapid pathogen ID molecular diagnostic.

Despite the array of tests available, some lab directors are still seeking broader functionalities and capabilities from the systems they purchase.  

While reimbursement and regulatory issues may make some cautious, investors are encouraged by the promise of breakthrough outcomes in a variety of applications.

Qiagen has extended the offer period for its DKK683 million ($103.5 million) acquisition of Exiqon.

OpGen will add a commercial data visualization portal to its CLIA testing service and launch an integrated product and services offering this year.

OpGen attributed the rise to sales of infectious disease diagnostics products from its AdvanDx acquisition and lab services based on the Acuitas MDRO suite.

The infectious disease diagnostics and bioinformatics firm will use the money for sales, marketing, R&D, and general corporate purposes a year after going public.

Pages

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.